Home / Business and Economy / Indian Pharma Rockets: $130B by 2030!
Indian Pharma Rockets: $130B by 2030!
16 Jul
Summary
- Indian pharma market to hit $130B by 2030.
- Exports grew 16x from FY2001 to FY26.
- FIIs increase stakes in IOL Chemicals & Granules India.
As of March 2026, India's pharmaceutical market stood at approximately $60 billion, with projections indicating a substantial rise to $130 billion by 2030. This growth trajectory solidifies its position as a major global player, currently ranking third by volume and eleventh by value.
Pharma exports from India demonstrated remarkable expansion, reaching $30.5 billion in FY26, a sixteenfold increase from $1.9 billion in FY2001. Government initiatives like Biopharma Shakti are further expected to accelerate research and development.
Foreign Institutional Investors (FIIs) have shown increased interest, boosting their holdings in select pharmaceutical stocks during Q1FY27. This includes significant stake increases in IOL Chemicals & Pharmaceuticals and Granules India.
IOL Chemicals, the world's largest integrated Ibuprofen producer, saw FIIs raise their stake by 3.15% points. The company is diversifying its product portfolio, with non-Ibuprofen revenue growing substantially, alongside its specialty chemicals segment.
Granules India is strategically shifting towards complex generics, which constituted 43% of finished goods in FY26, aiming for over 50%. They have also ventured into the peptide CDMO business with the acquisition of Senn Chemicals.
Both companies are undertaking significant capital expenditure for expansion. IOL Chemicals is developing a new 100+ acre site, while Granules India is building a 10 billion dosage facility, investing heavily in future growth capacities.
